Share
News
-
24 September 2010 /Side effects and trials
EMA recommends suspension of rosiglitazone-containing medicines (Avandia®, Avandamet® and Avaglim®)
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has reviewed the benefits and risks of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim) used in diabetes care.
-
22 September 2010 /Side effects and trials
Octagam® recalled by the Danish Medicines Agency
Based on increased reports of blood clots from the use of Octagam® 50 mg/ml in 2010, the Danish Medicines Agency has decided to recall Octagam® in Denmark. Octagam® is available in two strengths (50 mg/ml and 100 mg/ml) both of which are recalled.
-
15 September 2010 /Side effects and trials
React to serious and unexpected side effects
In week 37 the Danish Medicines Agency launches a nationwide campaign, setting out to encourage hospital doctors to be more active in reporting serious and unexpected side effects from medicine. The Danish Medicines Agency runs this campaign because it estimates that whenever one side effect is reported by a hospital doctor another 50 serious or unexpected side effects go unreported.
